Deskripsi produk
Indikasi
Mirdametinib is the first and only therapy approved in the European Union for adults and children 2 years of age and older with neurofibromatosis type 1-associated plexiform neurofibromas (NF1-PN).
Mekanisme Kerja
Mirdametinib Mekanisme Kerja Mekanisme Kerja ,
Dosis dan Penggunaan
2 GOMEKLI 2 mg/m², , , 28 21 GOMEKLI (2) 2.1 GOMEKLI GOMEKLI [ Peringatan (5.1)] (EF)[ Peringatan (5.2)] 2.2 GOMEKLI GOMEKLI GOMEKLI ,
Peringatan
5 Peringatan GOMEKLI , , , , GOMEKLI (5.1) GOMEKLI , , 3 , GOMEKLI (5.2) , , GOMEKLI
